Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MRK

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Benzinga

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients

Merck Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s (OTC:RHHBY) Avastin (bevacizumab).

Benzinga

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck & Co. Earnings Preview: What to Expect

Healthcare giant Merck & Co. is gearing up to unveil its third-quarter results by the end of October, and analysts expect a massive surge in earnings.

Barchart

Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients

Merck Co. Inc. (NYSE:MRK) announced results Tuesday from its Phase 3 HYPERION trial evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression.

Benzinga

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Benzinga

FDA Clears Merck's One-Minute Cancer Shot

The U.S. Food and Drug Administration (FDA) on Friday approved Merck Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for Keytruda.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug

On Friday, a European agency adopted two positive opinions for Merck Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab).

Benzinga

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Benzinga

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.

Benzinga

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data

Merck Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference.

Benzinga

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation…

Benzinga

This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Merck Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

Benzinga

Is Merck Stock Outperforming the Dow?

As Merck has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

On Tuesday, Merck Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

Barchart

Is Wall Street Bullish or Bearish on Merck Stock?

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.

Barchart

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

Benzinga

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Barchart

S&P Futures Gain With Focus on U.S. JOLTs Report and Corporate Earnings, FOMC Meeting on Tap

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors shift their focus from recent U.S. trade deals to economic data, a new round of corporate earnings reports, and the start of the Federal Reserve’s two-day policy meeting.

Benzinga

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

Merck Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29.

Barchart

What You Need To Know Ahead of Merck's Earnings Release

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Barchart

Is Merck Stock Underperforming the Nasdaq?

Despite Merck’s recent underperformance relative to the Nasdaq, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Merck Stock?

While Merck has trailed the broader market over the past year, analysts still see a reasonably promising path ahead for the pharma heavyweight.

Barchart

Do Wall Street Analysts Like Pfizer Stock?

Pfizer has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.